Drug Manufacturing

Nona Biosciences and Atossa team up to discover breast cancer therapies

Nona Biosciences has entered into a research collaboration with Atossa Therapeutics for the discovery of next-generation antibody therapies for treating breast cancer.

Imbria secures $57.5m to advance ninerafaxstat through Phase IIb nHCM trial

Imbria Pharmaceuticals has secured $57.5m in a Series B funding round to support the progression of ninerafaxstat through a double-blind Phase IIb FORTITUDE-HCM trial in non-obstructive hypertrophic cardiomyopathy (nHCM).

Renovaro closes merger transaction with BioSymetrics

Renovaro Biosciences has completed its merger with AI-driven drug discovery and precision neurology firm, BioSymetrics.

France 2030 funds 4MB’s knee osteoarthritis drug trial

4P-Pharma spin-off 4Moving Biotech (4MB) has received €7.6m ($8.3m) in funding from the France 2030 plan to expedite the clinical development of 4P004 for knee osteoarthritis, currently in a Phase IIa clinical trial.

FDA grants breakthrough therapy status for Amgen’s Uplizna to treat IgG4-RD

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Amgen’s humanised monoclonal antibody Uplizna (inebilizumab-cdon) to treat the adult population with immunoglobulin G4-related disease (IgG4-RD), an immune-mediated inflammatory condition that impacts several organs.

FDA clears Epicrispr’s application for FSHD treatment

The US Food and Drug Administration (FDA) has granted clearance for an investigational new drug (IND) application of Epicrispr Biotechnologies’ EPI-321, intended for treating genetic neuromuscular condition, facioscapulohumeral muscular dystrophy (FSHD).

EC grants orphan designation for Pharvaris’ deucrictibant drug

Pharvaris has secured orphan designation from the European Commission (EC) for deucrictibant, an investigational drug for treating bradykinin-mediated angioedema.

NeuroNOS secures funding for autism treatment development

As a part of a broader investment round, Beyond Air’s subsidiary NeuroNOS has received an initial equity financing of $2m from private investors, aimed at expediting the preclinical development of its small-molecule drug for paediatrics with autism.

Duke-NUS and NUS Medicine launch centre for metabolomics research

A collaborative effort between Duke-NUS Medical School and the National University of Singapore Yong Loo Lin School of Medicine (NUS Medicine) has led to the launch of the joint research centre named Systems Metabolomics Centre (SysMeC), aimed at metabolomics research.